Conclusion

Future research needs as prioritized by a stakeholder group representing diverse perspectives focused on the need for more methodologically rigorous and applicable research to better understand the comparative effectiveness of antiviral treatments for HCV infection in antiviral-naïve patients. Clinical trials of all-oral, interferon-sparing regimens are ongoing and illustrate the rapidly evolving nature of HCV treatments.